Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $27,675.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 1,107 shares of the stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $25.00, for a total transaction of $27,675.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Anish Patel also recently made the following trade(s):

• On Thursday, May 9th, Anish Patel sold 260 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.06, for a total transaction of $6,515.60.
• On Monday, May 6th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.72, for a total transaction of $110,760.00.
• On Thursday, April 11th, Anish Patel sold 17,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.03, for a total transaction of $438,025.00.
• On Monday, April 8th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.60, for a total transaction of $90,675.00.
• On Wednesday, March 6th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The shares were sold at an average price of $15.64, for a total transaction of $76,245.00.

Enliven Therapeutics Stock Down 0.8 %

Shares of ELVN traded down $0.19 during trading hours on Thursday, hitting $23.81. The company had a trading volume of 388,823 shares, compared to its average volume of 250,335. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -10.87 and a beta of 1.05. The business has a fifty day moving average of $18.60 and a 200-day moving average of $15.37. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $26.00.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.09. On average, equities analysts expect that Enliven Therapeutics, Inc. will post -2.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds have recently bought and sold shares of ELVN. Janus Henderson Group PLC increased its position in Enliven Therapeutics by 74.8% during the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company's stock worth $12,604,000 after acquiring an additional 305,397 shares during the period. Baker BROS. Advisors LP bought a new position in Enliven Therapeutics in the 1st quarter valued at about $2,020,000. Blackstone Inc. bought a new position in Enliven Therapeutics in the 1st quarter valued at about $443,000. SG Americas Securities LLC bought a new position in Enliven Therapeutics in the 3rd quarter valued at about $157,000. Finally, EntryPoint Capital LLC bought a new position in Enliven Therapeutics in the 1st quarter valued at about $167,000. 95.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Mizuho assumed coverage on shares of Enliven Therapeutics in a research report on Tuesday, April 9th. They issued a "buy" rating and a $34.00 price objective on the stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.